Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone.
about
Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studiesAssessment of pancreatic β-cell function: review of methods and clinical applicationsSaxagliptin overview: special focus on safety and adverse effectsA systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetesSafety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus.Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitusAssessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials.Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes.Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience.Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis.DPP-4 inhibitors and lipids: systematic review and meta-analysis.Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular dataLong-term safety and tolerability of saxagliptin add-on therapy in older patients (aged ≥ 65 years) with type 2 diabetesDipeptidyl Peptidase-4 (DPP-4) Inhibitors In the Management of DiabetesSaxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.Emerging treatment options for type 2 diabetesEfficacy and safety of saxagliptin as add-on therapy in type 2 diabetes.Saxagliptin for type 2 diabetesOverview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease.Diabetes: glycaemic control in type 2 (drug treatments).A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy.Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials.Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus.Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs.Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease.Incretin therapy--present and future.The role of incretin therapy at different stages of diabetes.Adenylyl Cyclase Type 5 Deficiency Protects Against Diet-Induced Obesity and Insulin ResistanceOptimizing the Care of Patients With Type 2 Diabetes Using Incretin-Based Therapy: Focus on GLP-1 Receptor Agonists.Update on Safety Issues Related to Antihyperglycemic TherapyDifferential HbA1c response in the placebo arm of DPP-4 inhibitor clinical trials conducted in China compared to other countries: a systematic review and meta-analysis.Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial.Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials.Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety.Therapy in the early stage: incretins.Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus.The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysisSaxagliptin Efficacy and Safety in Patients With Type 2 Diabetes and Moderate Renal Impairment.Clinically relevant reductions in HbA1c without hypoglycaemia: results across four studies of saxagliptin.Blood Glucagon Levels Predict the Hemoglobin A1c Response to Saxagliptin in Patients with Type 2 Diabetes Inadequately Controlled with Metformin.
P2860
Q26765047-612CC9DA-4574-4AEC-9B3C-25B408EACBEBQ26829445-7B0AB7A2-0DA3-42C4-BFB7-483DF2D851E2Q28278863-23479BC0-F71F-44D1-83F1-C11DA4C2D555Q28282265-6288A291-2DB9-41DE-9298-DEC499861192Q33412360-A35FB0AC-84FF-4204-8FA3-D3A90234E163Q33607742-422A4F81-B70F-444D-A2DC-AD0B9CA10075Q33732627-7845670E-A35C-4E7F-B2B0-ADBFDB5C7C42Q33886865-6F042CEF-C96C-4148-9F8E-9B90FF6CC6CEQ34068749-3E2DD634-45FB-418D-89E7-127C84081321Q34078449-52BB41E8-7EBE-4413-ADAD-CE2FFC52BE5BQ34116689-4794BE53-725E-4BEB-A2FA-B3E7BAF3DB06Q34128612-A8A94AED-CF8E-4ECC-932B-BE366C980AE5Q34154661-0F4629A0-736B-4B31-9F97-29946DDB2FEFQ34214474-D5EC0E44-9698-4EA8-9653-784A39CF42CBQ34239784-91920632-9386-4193-9F35-D086C2FA5146Q34381281-CC204550-4DDD-47CF-9821-0E8C5F0E025FQ34454269-694C030E-CF76-4604-B586-DB324624A0EDQ34620486-A0F9EAAB-A631-4CD3-BC39-2939215BE900Q34783302-F07F711C-77FC-4CEF-BA15-CDCA89D33C24Q34829290-C880E172-DF70-4F83-92A3-75A5446BF218Q35102138-5B2260E4-7C47-492D-AD69-8C38CCFA0442Q35236019-E48966A6-45ED-4322-80E6-EFD09302E28BQ35411329-7274DEC7-6304-4F04-8A14-F198928665BFQ35497064-0AB20D00-D111-42C3-853F-746A71283682Q35717211-A3E9761C-AF33-4B1A-AD96-D93450B26D88Q35760283-E85ABC04-886C-4535-B3D2-DA9D26D99ACEQ35760288-831440E9-B41F-4C0A-B327-48A99F8237EFQ35769605-CAD718D1-845B-493F-BF55-DB06D23ED0B4Q35906506-01C0B5EA-F27F-484D-9360-0F7D39D4C21DQ35910429-BD0A0544-44AF-4BD0-91A9-1DCBD7568ABEQ36124544-B4299B78-10A0-46AD-A551-81EDBE84A072Q36249636-91197624-DDDD-4232-BAA5-6814BEFA5B52Q36315963-874432E0-CC61-4BCF-B9A3-D2F1C0FBA7E8Q36327126-32F56CB9-20A9-4D96-862B-09722597CA3CQ36783865-2B1BB231-75E4-40C7-BBBD-1463A450B524Q36785098-C5DD5BCB-A61A-406D-A921-8E81ECAF2E23Q37030680-4CE61FE0-9F82-46B0-8819-B1FA21807704Q37239303-3AF5594E-1267-4DD0-B69E-BAE6FAE755E8Q37346737-3AAC2924-12F0-4D96-A52F-58B8864A58CFQ37427298-582EF580-CD20-4260-943B-288D5F8B19CC
P2860
Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone.
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Saxagliptin added to a thiazol ...... ol on thiazolidinedione alone.
@ast
Saxagliptin added to a thiazol ...... ol on thiazolidinedione alone.
@en
Saxagliptin added to a thiazol ...... ol on thiazolidinedione alone.
@nl
type
label
Saxagliptin added to a thiazol ...... ol on thiazolidinedione alone.
@ast
Saxagliptin added to a thiazol ...... ol on thiazolidinedione alone.
@en
Saxagliptin added to a thiazol ...... ol on thiazolidinedione alone.
@nl
prefLabel
Saxagliptin added to a thiazol ...... ol on thiazolidinedione alone.
@ast
Saxagliptin added to a thiazol ...... ol on thiazolidinedione alone.
@en
Saxagliptin added to a thiazol ...... ol on thiazolidinedione alone.
@nl
P2093
P356
P1476
Saxagliptin added to a thiazol ...... ol on thiazolidinedione alone.
@en
P2093
CV181-013 Investigators
Elsie Allen
Priscilla Hollander
Roland Chen
P304
P356
10.1210/JC.2009-0550
P407
P577
2009-10-28T00:00:00Z